logo-loader
viewValiRx PLC

ValiRx says YA II has converted second tranche of convertible loan facility at 1.25p per share

The life sciences company said YA II has elected to convert US$696,202.90 of its loan note, plus accrued interest of US$10,530, into 47,765,035 ordinary shares

Dollars
It added that US$520,000, plus interest, on Tranche 2 of the convertible remains outstanding

ValiRx Plc (LON:VAL) has announced that YA II Limited has converted the second tranche of its convertible loan facility at an agreed conversion price of 1.25p per share.

The life sciences company - which focuses on clinical stage cancer therapeutic development – said YA II has elected to convert US$696,202.90 of its loan note, plus accrued interest of US$10,530, into 47,765,035 ordinary shares at the agreed conversion price.

READ: ValiRx surges as it raises £1mln at a premium and confirms VAL401 phase II trial on track for readout this year

The group said the conversion is  subject to the passing of resolutions to be proposed to the company’s  shareholders at the general meeting on 21 December 2017.

ValiRx said the agreed conversion price supersedes the conversion formulae stated in the original loan note announcement dated 2 September 2016.

It added that US$520,000, plus interest, on Tranche 2 of the convertible remains outstanding.

In late afternoon trading ValiRx shares, which have been on a run recently after it confirmed its VAL401 phase II trial is on track for a readout before the year-end, were changing hands at 2.95 each, up 8.3%, or 0.22p on last night’s close.

Quick facts: ValiRx PLC

Price: 7.25 GBX

AIM:VAL
Market: AIM
Market Cap: £2.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ValiRx Plc enjoying strong industry interest in its cancer treatments

George Morris, chief operations officer at ValiRx Plc (LON:VAL), updates Proactive's Andrew Scott on developments across the company's portfolio. Morris says advanced conversations are continuing with possible partners as they look to press ahead with the development of their flagship...

on 19/7/18

2 min read